<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363743">
  <stage>Registered</stage>
  <submitdate>22/02/2013</submitdate>
  <approvaldate>27/03/2013</approvaldate>
  <actrnumber>ACTRN12613000338763</actrnumber>
  <trial_identification>
    <studytitle>Haploidentical donor stem cell transplantation for haematological malignancies -  a Phase 1/2 pilot study in an Australian population</studytitle>
    <scientifictitle>A comparison of leukaemia free and overall survival following Haploidentical donor stem cell transplantation compared to matched unrelated donor stem cell transplantation for haematological malignancies 
</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Haematological malignancies</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients are given Peripheral blood stem cells (PBSCs) collected from a haploidentical family member after completing myeloablative chemotherapy. 

The myeloablative chemotherapy consists of the following:

* Cytosine arabinoside 2g/m^2 twice daily by intravenous infusion on Days -10 &amp; -9

* Busulfan 3.2mg/kg/day by intravenous infusion on Days -8 to -6 (Pharmacokinetically monitored and adjusted to target AUC 4500micrometre/min)

* Cyclophosphamide 1.8g/m^2/day by intravenous infusion on days -5 &amp; -4

* CCNU (Lomustine) 200mg/m^2 by oral administration on Day -3 only

* ATG (thymoglobuline) 2.5mg/kg/day by intravenous infusion on Days -5 to -2

On day 0 participants then undergo infusion of unmanipulated GCSF primed bone marrow harvest +/PBSC supplementation (on second day 0) to achieve MNC &amp; CD34

minimum thresholds (&gt;4.0x10^8/kg &amp; &gt;2.0x10^6/kg respectively).

All participants will also undergo a GVHD prophylaxis regimen, which consists of:

* Cyclosporin 2.5mg/kg/day initially by intravenous infusion thence orally once tolerated from Day -9; At day +45 cyclosporin taper should be commenced (unless active GVHD) ~10% per month

* Mycophenolate 0.5g orally twice daily from Day -9; to be ceased on day +60 (unless active GVHD)

* Methotrexate 15mg/m^2 by intravenous infusion on Day +1

* Methotrexate 10mg/m^2 by intravenous infusion on Days +3,+6,+11

* GCSF 5mcg/kg subcutaneously daily until neutrophil recovery of &gt;2.0x10^9/L for at least 2 days.

</interventions>
    <comparator>Compare the results with historical results of St Vincent's Hospital patients who have undergone a standard of care allogeneic stem cell transplant over 12 month period from Feb 2011 to  Feb 2012. </comparator>
    <control>Historical</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Leukaemia free survival determined by clinical assessment, full blood count and bone marrow examination. </outcome>
      <timepoint>3, 6,  9, 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overall Survival is a clinical endpoint defined as time to death</outcome>
      <timepoint>3, 6,  9, 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Rates of acute Graft vs Host Disease (GVHD), assessed clinically and with laboratory investigations, according to standard definitions. </outcome>
      <timepoint>Day 100</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rates of chronic Graft vs Host Disease (GVHD) determined clinically.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to neutrophil and platelet engraftment, determined by full blood counts.</outcome>
      <timepoint>Day 30 </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ongoing  complete remission of underlying haematological malignancy
Absence of a 100% matched or single-mismatch related donor or single umbilical cord blood with 4/6 HLA match.
Presence of 1 haploidentical famiy donor
Absence of active fungalor viral (inc CMV) infection.
ECOG&lt;2
Preserved cardiac/renal/liver function</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Life expectance &lt;3 months.
Psychiatric condition interfering with informed consent.
History of active malignant disease within 5 yrs excl SCC or BCC of skin.
Previuos allogeneic stem cell transplant
Taking other 'investigational' drugs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>open label</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>4/05/2009</anticipatedstartdate>
    <actualstartdate>4/05/2009</actualstartdate>
    <anticipatedenddate>28/02/2014</anticipatedenddate>
    <actualenddate>10/06/2013</actualenddate>
    <samplesize>5</samplesize>
    <actualsamplesize>4</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincent's Hospital (Darlinghurst) - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital,Sydney</primarysponsorname>
    <primarysponsoraddress>390 Victoria St
Darlinghurst NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St Vincent's Hospital,Sydney
</fundingname>
      <fundingaddress>390 Victoria St
Darlinghurst NSW 2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to evaluate the effect of haploidentical donor stem cell transplantation in patients with haematological malignancies. 
Who is it for? You may be eligible to join this study if you are aged between 16-50 years and have ongoing complete remission of underlying haematological malignancy. You should have available a haploidentical family donor. This is a donor who is a 50% match, and can be a parent, sibling or child. 
Trial details All participants in this trial will undergo ten days of chemotherapy treatment, followed by infusion of peripheral blood stem cells (PBSCs) from the donor into the vein (i.e. intravenously). Participants will also be administered a number of medications to prevent graft versus host disease (GVHD), which is a common complication following stem cell transplantation. Patients will be regularly assessed for up to 12 months in order to evaluate clinical efficacy and safety of treatment. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>St Vincents Hospital 
390 Victoria St
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate>16/03/2009</ethicapprovaldate>
      <hrec>HREC/08/SVH/183</hrec>
      <ethicsubmitdate>9/12/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Anthony Dodds</name>
      <address>Kinghorn Cancer Centre
St Vincents Hospital 
370 Victoria St
Darlinghurst NSW 2010</address>
      <phone> 61 2 9355 5656</phone>
      <fax>61 2 9355 5735</fax>
      <email>svhcancer_research@stvincents.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Patricia Plenge</name>
      <address>Kinghorn Cancer Centre
St Vincents Hospital 
370 Victoria St
Darlinghurst NSW 2010</address>
      <phone>61 2 9355 5656</phone>
      <fax>61 2 9355 5735</fax>
      <email>svhcancer_research@stvincents.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Anthony Dodds</name>
      <address>Kinghorn Cancer Centre
St Vincents Hospital 
370 Victoria St
Darlinghurst NSW 2010</address>
      <phone>61 2 9355 5656</phone>
      <fax>612 9355 5735   </fax>
      <email>svhcancer_research@stvincents.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>patricia Plenge </name>
      <address>St Vincent's Hospital, sydney </address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>